文献速递胃肠外科围术期管理与 ERAS

全胃切除与食管切除术后生物可降解细胞外基质强化食管吻合的II期试验

Phase II Trial Evaluating Esophageal Anastomotic Reinforcement with a Biologic, Degradable, Extracellular Matrix after Total Gastrectomy and Esophagectomy.
PubMed 文献 · J Am Coll Surg · 2022-01-01

这项单中心非随机II期试验评估了生物可降解细胞外基质(ECM)强化食管吻合的安全性与减少吻合口漏的疗效。ECM置入总体可行且安全,但未显著降低吻合口漏。

要点

  • ECM强化吻合可行,75例中9例(12%)无法置入。
  • 临床显著吻合口漏率9.1%,与匹配队列无差异(p=0.57)。
  • 未报告ECM相关不良事件,但12.5%发生需侵入治疗的狭窄。

核心结论

  • 全胃切除或食管切除术后用生物可降解ECM强化食管吻合总体可行且安全,但未显著降低吻合口漏。

研究设计与样本

  • ECM组66例与按手术类型和年龄匹配的队列比较。

主要发现

  • 75例中9例(12%)ECM置入不可行,最终66例接受ECM。
  • 全胃切除50例(76%),食管切除16例(24%)。
  • 临床显著吻合口漏6/66(9.1%):全胃切除后3/50(6.0%),食管切除后3/16(18.8%),与匹配队列无差异(p=0.57)。
  • 需侵入治疗的狭窄8例(12.5%),术后第90天10例(15.6%)报告不能正常进食。
  • 未报告ECM相关不良事件。

临床怎么用

  • ECM强化食管吻合可作为可行且安全的选择,但不应期望其显著降低吻合口漏。
  • 术后需关注吻合口狭窄及进食功能,术后第90天仍有部分患者不能正常进食。

局限性

  • 单中心、非随机设计,样本量有限。
  • 与匹配队列比较,非随机对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A biologic, degradable extracellular matrix (ECM) has been shown to support esophageal tissue remodeling, which could reduce the risk of anastomotic leak following total gastrectomy and esophagectomy. We evaluated the safety and efficacy of reinforcing the anastomosis with ECM in reducing anastomotic leak as compared to a matched cohort. STUDY DESIGN: In this single-center, nonrandomized phase II trial, gastric or esophageal adenocarcinoma patients undergoing total gastrectomy or esophagectomy were recruited from November 2013 through December 2018. ECM was surgically wrapped circumferentially around the anastomosis. Anastomotic leak was assessed clinically and by contrast study and defined as clinically significant if requiring invasive treatment (grade 3 or higher). Anastomotic stenosis, other adverse events, symptoms, and dysphagia score were collected by standardized forms at regular follow-up visits at approximately postoperative days (POD) 21 and 90. Patients receiving ECM were compared to a cohort matched for surgery type and age. RESULTS: ECM placement was not feasible in 9 of 75 patients (12%), resulting in 66 patients receiving ECM. Total gastrectomy was performed in 50 patients (76%) and esophagectomy in 16 (24%). Clinically significant anastomotic leak was diagnosed in 6 of 66 patients (9.1%) (3/50 [6.0%] after gastrectomy, 3/16 [18.8%] after esophagectomy); this rate did not differ from that in the matched cohort (p = 0.57). Stenosis requiring invasive treatment occurred in 8 patients (12.5%), and 10 patients (15.6%) reported not being able to eat a normal diet at POD 90. No adverse events related to ECM were reported. CONCLUSIONS: Esophageal anastomotic reinforcement after total gastrectomy or esophagectomy with a biologic, degradable ECM was mostly feasible and safe, but was not associated with a statistically significant decrease in anastomotic leak.

来源:J Am Coll Surg,查看原文。版权归原作者所有。

引用

  1. Vos EL, Nakauchi M, Capanu M, et al. Phase II Trial Evaluating Esophageal Anastomotic Reinforcement with a Biologic, Degradable, Extracellular Matrix after Total Gastrectomy and Esophagectomy. J Am Coll Surg. 2022. PMID: 35426405. doi:10.1097/XCS.0000000000000113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。